medRxiv preprint doi: https://doi.org/10.1101/2020.04.28.20082677; this version posted May 2, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Fixed-Life or Rechargeable Battery for Deep Brain Stimulation: Preference and Satisfaction in Chinese Patients with Parkinson's Disease

Xian Qiu[1,2*], Tingting Peng[1*], Zhengyu Lin[1], Kaiwen Zhu[1], Yuhan Wang[1], Bomin Sun[1], Keyoumars Ashkan[3], Chencheng Zhang[1], Dianyou Li[1]

[1]Department of Functional Neurosurgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China

[2]School of Nursing, Shanghai Jiao Tong University, Shanghai, China

[3]Department of Neurosurgery, King's College Hospital, London, UK

*These two authors contributed equally to this work.

Correspondance :

Chencheng Zhang i@cczhang.org

Dianyou Li ldy11483@rjh.com.cn

medRxiv preprint doi: https://doi.org/10.1101/2020.04.28.20082677; this version posted May 2, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Abstract

Objective

To evaluate the preference and satisfaction in the Chinese Parkinson's disease (PD) patients treated with deep brain stimulation (DBS).

Background

DBS is a widely used therapy for PD. There is now a choice between fixed-life implantable pulse generators (IPGs) and rechargeable IPGs, each having their advantages and disadvantages.

Methods

Two hundred and twenty PD patients treated with DBS completed a self-designed questionnaire to assess long-term satisfaction and experience with the type of battery they had chosen, and the key factors affecting their choices. The survey was performed online and double-checked for completeness and accuracy.

Results

The median value of follow-up length was 18 months. 87.3% of the DBS used rechargeable IPGs (r-IPG). The choice between rechargeable and non-rechargeable IPGs was significantly associated with the patient's affordability ($\chi^2_{(1)} = 19.13$, $p < 0.001$). Interestingly, the feature of remote programming significantly affected patients' choices between domestic and imported brands ($\chi^2_{(1)} = 16.81$, $p < 0.001$). 87.7% of the patients were satisfied with the stimulating effects as well as the implanted device. 40.6% of the patients with r-IPGs felt confident handling their devices within one week after discharge. More than half of the patients checked their batteries every week. The mean interval for battery recharge was 4.3 days. 57.8% of

medRxiv preprint doi: https://doi.org/10.1101/2020.04.28.20082677; this version posted May 2, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

the patients spent around one-hour recharging and 71.4% of them recharged the battery independently. The most popular way for patients to learn about DBS surgery was through media (79/220, 35.9%), including the Internet and television programs. The rehabilitation (40.6%, 78/192), and programming (36.5%, 70/192) were two main courses that most patients wanted to learn after surgery.

Conclusion

Most patients were satisfied with their choices of IPGs. The patients' financial status and remote programming function were the two most critical factors in their decision. The skill of using rechargeable IPG was easy to master by most patients.

medRxiv preprint doi: https://doi.org/10.1101/2020.04.28.20082677; this version posted May 2, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Introduction

Deep brain stimulation (DBS) is a widely used treatment for Parkinson's disease (PD), which achieves its effects by continuous application of electrical currents. The power comes from an implantable pulse generator (IPG), which was originally designed to be non-rechargeable. These IPGs/batteries typically lasted three to five years, depending on the diagnosis and parameter settings, before they had to be replaced. As the energy consumption in continuous DBS is high, battery depletion is the most common cause for further surgery in DBS patients. [1,2] Although an IPG replacement is a minor surgical procedure compared with the primary operation, infection risk and wound healing (eg. scar formation, skin thinning) can become problematic after several IPG replacements. [3]

Rechargeable batteries were introduced in 2008 and offer a number of advantages over fixed-life batteries, including longer battery life, requiring fewer battery replacement surgeries, less battery depletion–related problems (symptom deterioration and injuries), and a smaller profile. [4] Studies examining the use of rechargeable batteries for DBS have demonstrated that they are well tolerated, having high patient satisfaction rate, and can be cost-effective. However, patients need to check their battery status and recharge regularly, by using a handheld device. Recharge frequency and duration depend on patient's individual power consumption. Although it is not difficult to perform, the recharge process can be challenging for DBS patients as most of them are elderly PD patients with various level of cognitive deficits. [5]

medRxiv preprint doi: https://doi.org/10.1101/2020.04.28.20082677; this version posted May 2, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

In addition to battery options, rapid technological development in the last decade has made neurologists and neurosurgeons–face the challenge of selecting an ideal individualized DBS system based on multiple variables such as lead geometry and different programming platforms.[6] Factors including DBS target, the amount of current needed, patient's overall health condition and their ability to deal with interactive devices and recharging, social support network, and personal financial status are of prime importance in delivering individualized therapy to patients. Another critical area which has not been fully explored is the influence of patient's individual preferences and lifestyle concerns on the choice of the DBS device. Patient's decision on DBS battery choice and the influencing factors of the decision have only been investigated in a few studies in Europe. [5,7–9]

Neuromodulation with implantable devices is one of the most technologically driven discipline within neurosurgery. In recent years, there has been a considerable expansion in choices of available DBS hardware allowing for more personalized therapies, maximizing the benefits and acceptability, whilst minimizing the risks. At the same time, DBS specialists also face the challenge of selecting among a mass of options to choose the most appropriate device for each patient. Understanding why and how patients make their choices is critical not only to improve patient acceptability and satisfaction of the therapy, but also to innovate the next generation devices. In China, three DBS manufacturers (Medtronic, PINS and SceneRay) are currently offering non-rechargeable (nr-IPG) and rechargeable IPGs (r-IPG) from 1998 and 2013, 2013 and 2014, 2016 and 2019, respectively (Supplemental Figure 1). In this article, we sought to report patients' satisfaction and preferences for the type of IPGs they chose.

medRxiv preprint doi: https://doi.org/10.1101/2020.04.28.20082677; this version posted May 2, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Method

Participants

Patients diagnosed with idiopathic PD who had undergone DBS surgery in the Department of Functional Neurosurgery in Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine were invited to participate in this survey. Patients implanted with either nr-IPG or r-IPG were included in this study. 768 patients with PD who had received DBS surgeries in our center were contacted for this study.

Questionnaire

An internet-based questionnaire (powered by www.wjx.cn) was developed and was distributed via an online chat software Wechat. The questions comprised of various aspects of the DBS devices that the patients had chosen, including (but not limited to) patients' demographics, factors that impacted patients' choices, patients' satisfaction about their choices and DBS surgery. In particular, several questions were designed specifically for patients with an r-IPG device: the feasibility and reliability of the battery recharge, the interval and duration of the recharge, and the convenience of post-operative management of r-IPG. All patients provided their consent for data collection and analysis at the beginning of the questionnaire before study participation. This study was approved by Ruijin Ethical Committee.

Statistical analysis

medRxiv preprint doi: https://doi.org/10.1101/2020.04.28.20082677; this version posted May 2, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Data were analyzed with the SPSS software (Version 23.0. Amonk, NY: IBM Corp.). Continuous variables were expressed as Mean ± SD or median value with interquartile range (IQR). Categorical variables were presented as frequencies (%). We used Fisher's exact test to assess the–relationship between patient's affordability and the choice of r-IPG versus nr-IPG. We used Pearson's or Yates' continuity corrected Chi-square test to evaluate the influencing factors for patients' choices of international versus domestic manufacturers in r-IPG group, and to compare the satisfaction rate between patients with r-IPG and nr-IPG. A p-value < 0.05 was considered significant.

Results

Demographic data

220 patients (135 men and 85 women) with PD completed the survey and were available for analysis. The response rate was 28.6% (220/768). Among them, 192 (87.3%) patients were implanted with r-IPGs and 28 (12.7%) patients with nr-IPGs. 142 (64.5%) patients had chosen a device from the international manufacturer (i.e., Medtronic) and 78 (35.5%) patients had chosen a device from domestic manufacturers (i.e., PINS or SceneRay). Overall, the mean age was 62.8 ± 9.8 years. The median value of the follow-up length was 18 (IQR: 8–36) months. Demographic data was listed in Table 1.

Source of DBS information

medRxiv preprint doi: https://doi.org/10.1101/2020.04.28.20082677; this version posted May 2, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

The web and television media and doctor's referrals served as two important tunnels for PD patients to know DBS before seeking for surgery [36.1% (79/219) and 35.6% (78/219), respectively]. The remaining quarter of the patients (25.5%, 56/219) came to our center learned the information about DBS by the word of mouth from other patients (Table 2).

Influencing factors for patients' choices of rechargeable versus non-rechargeable battery

As illustrated in Figure 1, approximately half of the patients (51.6%, 99/192) who had chosen r-IPGs had a budget between 200 to 300 thousands RMB, while 53.6% (15/28) of patients with nr-IPGs only had a budget between 100 to 200 thousands RMB. The choice of r-IPG versus nr-IPG was significantly associated with the patient's affordability ($p = 0.0001$). Concretely, the percentage of patient's reporting 'concern' or 'serious concern' about economic issues was higher in nr-IPG group (82.1%, 23/28) than that in r-IPG group (60.9%, 117/192) (Figure 2D). Interestingly, the need for further surgeries to replace the battery, as well as the need for recharging the battery, was considered a concern or a serious concern by 82.1% (23/28) and by 64.3% (18/28) of the patients with nr-IPGs, respectively, also higher than r-IPG group (72.9% (140/192) and 47.9% (92/192), respectively) (Figure 2B–2C). There was 46.4% (13/28) of the patients with nr-IPGs and 51.6% (99/192) of the patients with r-IPGs reported 'concern' or 'serious concern' about the size of battery (Figure 2A).

Influencing factors for r-IPG patients' choices between international and domestic manufacturers

medRxiv preprint doi: https://doi.org/10.1101/2020.04.28.20082677; this version posted May 2, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Among 192 patients with r-IPGs, 136 (70.8%) patients had chosen a device from the international manufacturer (i.e., Medtronic), and 56 (29.2%) had chosen a device from the domestic manufacturer (i.e., PINS or SceneRay). The patient's economic issue, international reputation of the product, as well as the product feature of remote programming significantly affected r-IPG patients' choices between international and domestic manufacturers (p = 6.28E-7, 5.40E-11, and 3.68E-7, respectively) (Figure 3A–3C). Not surprisingly, patient's choice was not influenced by clinicians (p = 0.202) (Figure 3D).

Satisfaction

The majority of the patients (87.7%, 193/220) were satisfied with stimulating effects as well as the implanted device. 10% (22/220) of them claimed that their expectation had not been met after the surgery. The satisfaction rate among patients with r-IPGs (88.0% 169/192) showed no statistical significance compared with those with nr-IPGs (85.7%, 24/28) (p = 0.969) (Table 3). Also, no statistical significance was observed for the satisfaction rate between international and domestic manufacturers in patients with r-IPGs (p = 0.729). 92.7% (178/192) of the patients with r-IPGs and 92.9% (26/28) with nr-IPGs would choose the same type of the device when completing the questionnaire.

Recharging process

The majority of the r-IPG patients (71.4%, 137/192) were capable of battery recharge independently. The remaining patients (28.6%, 55/192), however, needed partners to check and recharge the battery. Most of the patients with r-IPGs and their partners

medRxiv preprint doi: https://doi.org/10.1101/2020.04.28.20082677; this version posted May 2, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

(92.7%, 178/192) felt confident of handling their device; 43.8% (78/178) of them reported the same confidence within one week after discharge from hospital. More than half of the patients (64.1%, 123/192) checked the battery every week, and most r-IPG patients (92.2%, 177/192) preferred recharging when the battery level was over 50%. The mean interval for battery recharge was 4.3 days. More than half of the patients (57.8%, 111/192) spent around 1 hour recharging. Notably, 8.3% (16/192) of the r-IPG patients reported at least one episode of recharge failure at some point, and more than half of them (68.9%, 11/16) failed to perform troubleshooting (Table 4).

Life with a r-IPG

During the routine recharging process, most of the r-IPG patients (92.7%, 178/192) preferred to sit or lie down to moving around. Only 26.6% (51/192) of the r-IPG patients reported at least one travel history after implantation, 78.4% (40/51) of whom recharged during their vacation. 11.5% (22/192) of the r-IPG patients continued their professional occupation after the surgery, but only one patient had recharged the IPG at work (Table 5).

Discussion

This study presented patients' views independent of clinical influences and revealed that most patients, around 80%, opted for the rechargeable batteries. A significant factor contributing to this choice was related to economic status. Nevertheless, it is the effect of surgery other than the product being the main factor that determines patient satisfaction. The remote programming feature significantly affected patients' choice of products, which is now only available in Chinese domestic brands. The

medRxiv preprint doi: https://doi.org/10.1101/2020.04.28.20082677; this version posted May 2, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

recharging process is generally rated as "easy" and can be mastered within a rather short amount of time. Weekly intervals to check the battery status and to recharge are most common. The amount of time that needs to be invested by the patient to handle and recharge the IPG is around one hour. Our cohort showed that patients were able to continue their jobs and to travel with r-IPGs, but only few of our patients recharged their IPGs during work or travelling.

Neither age, nor education level had a significant impact on the understanding of the recharging process. Almost 25% of the patients have helpers to perform the recharging process. Interestingly, there were several patients checked their batteries every one year or more, which meant they recharged the IPG frequently but they did not check the IPG status as much. Although it was not reported in these participants, we had patients who failed to get timely recharge. Restarting power depleted IPGs needs continuous charging for more than 5 hours. In most cases, power depletion did not cause irreversible consequences, but one patient got aspiration pneumonia during the power off period.

In our center all patients were advised not to deplete their IPG below 50% of its capacity. More than 80% of our patients usually recharge when the remaining battery capacity is about 50%. We also demonstrated in our study that patients in the highest age group (70 years or older) did not necessarily have more difficulties than younger ones, and they did not rate the recharging process as more difficult than younger ones; while old age and bad functional status may be considered as factors against the use of a rechargeable IPG. Inability to recharge the IPG could be annoying and might

medRxiv preprint doi: https://doi.org/10.1101/2020.04.28.20082677; this version posted May 2, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

have serious adverse consequences. In our study, most cases' problems were caused by malfunctioning power banks that needed to be replaced. One patient reported that the device was shut down unexpectedly without patient's awareness, and the program controller was used to restart the IPG. Another case involved an elderly patient, whose new caregiver failed to recharge the IPG when the original caregiver was replaced at the nursing home.

Although we are not the first ones to report this patient collective, our cohort is—to the best of our knowledge—the largest reported one by far. Timmermann et al. [9]reported a prospective patient satisfaction study of 21 patients with 14 of them having initial implantation of r-IPGs over a three months follow-up. Unlike Timmermann et al., in which patient selection of r-IPG implantation was determined by clinical judgment of clinicians, our patients were offered a choice of r-IPG or nr-IPG, as well as of international or domestic brand, after a comprehensive and detailed explanation of each option. This study shares our finding that the amount of training does not associate with a higher rate of satisfaction. Jakobs et al.[5] reported a retrospective cohort with a mean follow-up of 21.2 months (10.0 months, 5–41 months) , in which 3/35 patients felt not confident of using their IPG but majority of the patients who felt not confident after their training session had only received a single training session. In our study, 178 (92.7%) patients felt confident of using their IPG, and we thought it is reasonable to have at least two training sessions with the patients and care givers: one session before discharge and one session at one week after discharge. The overall handling of the r-IPGs was reported as being "easy", which was similar to our results. The main point of critique was about putting on the charging belt, which was more often negatively rated than charging the charger. As

medRxiv preprint doi: https://doi.org/10.1101/2020.04.28.20082677; this version posted May 2, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

this seems to represent one major issue for patients, the manufacturers should pay special attention to improve and simplify the process of inductive recharging. Waln and Jimenez-Shahed et al.[10] reported patient satisfaction in a series of 31 patients of which 12 received r-IPGs as their initial implants. Interestingly, these patients were more satisfied with their IPGs compared with patients who previously had an nr-IPG implanted. In our study, we didn't explore the satisfaction rates between multiple products but found the therapy efficacy was the dominating factor of patients' general satisfaction.

Cost effectiveness is a critical reason to choose IPG. Although the price for an r-IPG is roughly twice as high as for an nr-IPG, the longevity of the implant may make it more cost efficient over time. Rizzi et al. calculated savings of more than 223,000 EUR in a 149-patient cohort over almost eight years in a hypothetical scenario when every patient had an r-IPG implanted instead of a non-rechargeable one[11]. However, reimbursement policies differ in different countries and cities. The choice of IPG may not be in the hands of patients and physicians alone but also in the hands of insurance agencies. Due to the various insurance policies in China, the cost effective investigation is beyond the scope of this survey.

Our study has several limitations. First, this study was undertaken in a single institution, so there might be inherent biases. Second, it is not a longitudinal study. We are not able to identify when the patients had adverse events or how user confidence and satisfaction developed over time. Third, although our study has a comparatively long mean follow-up and large sample size, it remains to be seen what aspects may

medRxiv preprint doi: https://doi.org/10.1101/2020.04.28.20082677; this version posted May 2, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

come into play when r-IPGs are near the end of the recommended run-time of nine years or more. Decreasing IPG capacities over time may result in shorter intervals between recharges and longer recharging process. Our study results apply to all of the three systems, which share the basic principles of recharging. We didn't find the difference in usability, recharging times and complication in three manufacturers.

In conclusion, we found most patients were satisfied with their choices of IPG. The patients' financial status and the product feature of remote programming were the two most critical factors in their decision. The skill of using rechargeable IPG was easy to be mastered by most patients.

Funding

This study was supported by the 2018 Shanghai Municipal Education Commission—Gaoyuan Nursing Grant Support (Hlgy1804kyx).

Acknowledgments

We thank Ms. Kaile Zhang and Dr. Luciano Furlanetti for their kind support in this study.

medRxiv preprint doi: https://doi.org/10.1101/2020.04.28.20082677; this version posted May 2, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

References

1. Kumar, N., Murgai, A. & Jog, M. Neurological Worsening After Implantable Pulse Generator Replacement. Can J Neurol Sci (2019).

2. Niemann, M., Schneider, G.-H., Kühn, A., Vajkoczy, P. & Faust, K. Clinical Efficacy of Bilateral Deep Brain Stimulation Does Not Change After Implantable Pulse Generator Replacement but the Impedances Do: A Prospective Study. Neuromodulation (2019).

3. Thrane, J. F., Sunde, N. A., Bergholt, B. & Rosendal, F. Increasing infection rate in multiple implanted pulse generator changes in movement disorder patients treated with deep brain stimulation. Ster. Funct Neurosurg (2014).

4. Hitti, F. L., Vaughan, K. A., Ramayya, A. G., McShane, B. J. & Baltuch, G. H. Reduced long-term cost and increased patient satisfaction with rechargeable implantable pulse generators for deep brain stimulation. J Neurosurg (2018).

5. Jakobs, M., Kloß, M., Unterberg, A. & Kiening, K. Rechargeable Internal Pulse Generators as Initial Neurostimulators for Deep Brain Stimulation in Patients With Movement Disorders. Neuromodulation (2018).

6. Okun, M. S. Tips for Choosing a Deep Brain Stimulation Device. JAMA Neurol. **76**, 749–750 (2019).

7. Furlanetti, L. et al. Fixed-Life or Rechargeable Battery for Deep Brain Stimulation: A Prospective Long-Term Study of Patient's Preferences. Ster. Funct Neurosurg (2020).

medRxiv preprint doi: https://doi.org/10.1101/2020.04.28.20082677; this version posted May 2, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

8. Khaleeq, T., Hasegawa, H., Samuel, M. & Ashkan, K. Fixed-Life or Rechargeable Battery for Deep Brain Stimulation: Which Do Patients Prefer? Neuromodulation (2019).

9. Timmermann, L. et al. A new rechargeable device for deep brain stimulation: a prospective patient satisfaction survey. Eur Neurol (2013).

10. Waln, O. & Jimenez-Shahed, J. Rechargeable deep brain stimulation implantable pulse generators in movement disorders: patient satisfaction and conversion parameters. Neuromodulation (2014).

11. Rizzi, M. et al. Internal Pulse Generators in Deep Brain Stimulation: Rechargeable or Not? World Neurosurg. **84**, 1020–1029 (2015).

medRxiv preprint doi: https://doi.org/10.1101/2020.04.28.20082677; this version posted May 2, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Figure legend

Figure 1. Patients' budgets for DBS surgery. Budgets were divided into four levels and indicated by different grayscales. Values were presented either in absolute patient number (A) or in percentage (B). Abbreviation: r-IPG = rechargeable IPG (N = 192); nr-IPG: non-rechargeable IPG (N = 28).

Figure 2. Influencing factors for choices of rechargeable versus non-rechargeable battery. The degree of influence was divided into five levels and indicated by different grayscales. Values were presented as percentage. (A) battery dimension; (B) need for further surgeries to replace the battery; (C) need for recharging the battery; (D) economic issue. Abbreviation: r-IPG = rechargeable IPG (N = 192); nr-IPG: non-rechargeable IPG (N = 28).

Figure 3. Influencing factors for choices of international versus domestic manufacturers in patients with rechargeable battery. Values were presented as percentage. (A) economic issue; (B) international reputation; (C) remote programming feature; (D) clinician's advice. In current Chinese DBS marketing, the international manufacturer refers to Medtronic (N = 136), and domestic manufacturers refer to PINS and SceneRay (N = 56).

Supplemental Figure 1. Size comparison between non-rechargeable (left column) and rechargeable (right column) implantable pulse generators from three manufacturers in China. (A) – (B) Medtronic; (C) – (D) PINS; (E) – (F) SceneRay.


A
B
p = 0.0001
Number of patients
250
200
150
100
50
0
39
99
45
9
9
15
4
r-IPG
(N = 192)
nr-IPG
(N = 28)
Percentage
1.0
0.8
0.6
0.4
0.2
0.0
0.20
0.52
0.23
0.05
0.32
0.54
0.14
r-IPG
(N = 192)
nr-IPG
(N = 28)
> 300 thousands Renminbi
200 to 300 thousands Renminbi
100 to 200 thousands Renminbi
< 100 thousands Renminbi


A
p = 0.419
Percentage
1.0
0.8
0.6
0.4
0.2
0.0
0.16
0.35
0.24
0.14
0.11
0.18
0.28
0.18
0.29
0.07
r-IPG
(N = 192)
nr-IPG
(N = 28)
B
p = 0.203
0.39
0.34
0.11
0.11
0.05
0.25
0.57
0.03
0.11
0.04
C
p = 0.408
0.18
0.30
0.17
0.22
0.13
0.29
0.36
0.18
0.14
0.03
D
p = 0.172
0.19
0.42
0.17
0.15
0.07
0.32
0.50
0.07
0.04
0.07
Serious concern
Concern
Neutral
No-concern
No-concern at all


A
p = 6.28E-7
B
p = 5.41E-11
C
p = 3.68E-7
D
p = 0.202
Yes
No
Percentage
1.0
0.8
0.6
0.4
0.2
0.0
0.11
0.89
0.43
0.57
0.52
0.48
0.02
0.98
0.10
0.90
0.41
0.59
0.62
0.38
0.52
0.48
Medtronic
PINS & SceneRay

medRxiv preprint doi: https://doi.org/10.1101/2020.04.28.20082677; this version posted May 2, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Table 1. Demographic data.

Characteristics	**Total**	**r-IPG**	**nr-IPG**
Gender			
Men	135	114	21
Women	85	78	7
Age, year (Mean ± SD)	62.8 ± 9.8	62.5 ± 9.8	64.4 ± 10.0
Follow-up, month (Median, IQR)	18 (8–36)	19 (9–38)	15.5 (5.25–26.5)
Manufacturer			
Medtronic	142	136	6
PINS & SceneRay	78	56	22

medRxiv preprint doi: https://doi.org/10.1101/2020.04.28.20082677; this version posted May 2, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Table 2. Approaches to learn about deep brain stimulation. (N = 219)*

Approaches	**Number (%)**
Media (i.e., Web and television)	79 (36.1%)
Doctor's referrals	78 (35.6 %)
Word of mouth from patients	56 (25.6%)
Others	6 (2.7%)

*One missing data.

medRxiv preprint doi: https://doi.org/10.1101/2020.04.28.20082677; this version posted May 2, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Table 3. Satisfaction rate.

Questions	**Group**	
	r-IPG	**nr-IPG**
	(N = 192)	**(N = 28)**
1. Are you still happy with your choice of your device?		
Yes	169 (88.0%)	24 (85.7%)
No	23 (12.0%)	4 (14.3%)
1.1. If not, please specify.		
The stimulating effects did not meet your expectation.	18 (9.4%)	4 (14.3%)
Others	5 (2.6%)	0
2. Would you choose the same type of your device today?		
Yes	178 (92.7%)	26 (92.9%)
No	14 (7.3%)	2 (7.1%)

medRxiv preprint doi: https://doi.org/10.1101/2020.04.28.20082677; this version posted May 2, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

1 **Table 4. Recharging process for patients with r-IPG. (N = 192)**

Questions	Number (%)
1. Do you feel confident using your r-IPG?	
No	14 (7.3%)
Yes	178 (92.7%)
1.1. If yes, how long did it take to feel confident?	
Within 1 week	78 (40.7%)
1–2 weeks	27 (14.1%)
2–4 weeks	8 (4.2%)
More than 4 weeks	65 (34.0%)
2. How frequently do you check battery capacity of your r-IPG?	
Everyday	35 (18.2%)
Every week	123 (64.1%)
Every 2 weeks	6 (3.1%)
Every 4 weeks	17 (8.9%)
Every year	11 (5.7%)
3. Have you ever forgotten to recharge your r-IPG?	
No	156 (81.3%)
Yes	36 (18.7%)
4. How frequently do you recharge your r-IPG?	
Everyday	49 (25.5%)
2–4 days	28 (14.6%)
5–7 days	115 (59.9%)
5. How frequently do you recharge your recharger?	

medRxiv preprint doi: https://doi.org/10.1101/2020.04.28.20082677; this version posted May 2, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Everyday	15 (7.8%)
Every week	104 (54.2%)
Every 2 weeks	31 (16.1%)
Every 4 weeks	37 (19.3%)
Not fixed	5 (2.6%)
6. At what level of battery capacity do you usually recharge your r-IPG?	
75–100%	101 (52.6%)
75–50%	76 (39.6%)
< 50%	15 (7.8%)
Warning sign	0
7. How long does recharging usually take?	
Less than 15 min	9 (4.7%)
15–30 min	37 (19.3%)
30–45 min	35 (18.2%)
45–60 min	40 (20.8%)
More than 60 min	71 (37.0%)
8. Do you check and recharge your r-IPG yourself?	
No	55 (28.6%)
Yes	137 (71.4%)
9. Have you ever been unable to recharge your battery?	
No	176 (91.7%)
Yes	16 (8.3%)
9.1. if yes, could you solve the problem on your own?	
No	11 (68.9%)

medRxiv preprint doi: https://doi.org/10.1101/2020.04.28.20082677; this version posted May 2, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Yes	5 (31.2%)

medRxiv preprint doi: https://doi.org/10.1101/2020.04.28.20082677; this version posted May 2, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Table 5. Life with a rechargeable IPG. (N = 192)

Questions	**Number (%)**
1. Have you ever travelled since your DBS surgery?	
No	141 (73.4%)
Yes	51 (26.6%)
1.1. If yes, have you ever recharged during the vacation?	
No	11 (21.6%)
Yes	40 (78.4%)
2. Do you continue to work after DBS surgery?	
No	170 (88.5%)
Yes	22 (11.5%)
2.1. If yes, have you ever recharged during the work?	
No	21 (95%)
Yes	1 (5%)
3. Are you ambulatory during recharging?	
No	178 (92.7%)
Yes	14 (7.3%)